GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Float Percentage Of Total Shares Outstanding

Ocugen (FRA:2H51) Float Percentage Of Total Shares Outstanding : 97.97% (As of Mar. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ocugen's float shares is 286.08 Mil. Ocugen's total shares outstanding is 292.01 Mil. Ocugen's float percentage of total shares outstanding is 97.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ocugen's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ocugen's Institutional Ownership is 19.38%.

Ocugen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ocugen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=286.08/292.01
=97.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
CTNM NAUT PROK LRMR MDWD INMB LYEL IKT PLRX FULC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
OCGN:USA OCGN:Mexico
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Website
https://www.ocugen.com
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ocugen Headlines

No Headlines